KR20200069737A - A composition for preventing, treating or improving alopecia comprising aptamin c - Google Patents
A composition for preventing, treating or improving alopecia comprising aptamin c Download PDFInfo
- Publication number
- KR20200069737A KR20200069737A KR1020180157134A KR20180157134A KR20200069737A KR 20200069737 A KR20200069737 A KR 20200069737A KR 1020180157134 A KR1020180157134 A KR 1020180157134A KR 20180157134 A KR20180157134 A KR 20180157134A KR 20200069737 A KR20200069737 A KR 20200069737A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- aptamin
- preventing
- treating
- dvl1
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Abstract
Description
본 발명은 비타민 C와 상기 비타민 C에 결합하는 압타머를 유효성분으로 포함하는 탈모증의 예방, 치료 또는 개선용 조성물에 관한 것이다.The present invention relates to a composition for preventing, treating or improving alopecia, comprising vitamin C and an aptamer binding to vitamin C as an active ingredient.
인체의 모발은 약 10만 ~ 15만 개 정도이며, 각각의 모발은 서로 다른 주기를 가지며 성장기, 퇴행기 및 휴지기를 반복한다. 이러한 주기의 반복을 통하여 머리카락이 빠지고 나고를 반복하게 된다. 이러한 모주기는 3~6년에 걸쳐 반복되는데 그 결과 일일 평균 100개 전후의 모발이 정상적으로 탈락하게 된다.The human body has about 100,000 to 150,000 hairs, and each hair has a different cycle and repeats the growth phase, degenerative phase, and resting phase. Through the repetition of this cycle, the hair falls out and repeats. This hair cycle is repeated over 3 to 6 years, and as a result, the average of 100 hairs per day falls off normally.
상기와 같이 사람의 모발은 모주기를 가지고 있기 때문에 털갈이 없이 항상 일정한 모발의 수를 유지하게 된다. 그러나 대머리가 진행되면 모근에 존재하는 유두가 작아지고, 모유두가 작아지면 머리털의 굵기도 가늘어지고 동시에 모주기도 짧아지며, 새로 자라나온 털은 더욱 가늘어지게 된다. 따라서 대머리가 진행되면 머리털은 솜털로 변하며 모주기는 더욱 짧아져 조금 자란 후 빠지게 된다.As described above, since human hair has a hair cycle, a constant number of hairs are always maintained without molting. However, when the baldness progresses, the nipples existing in the hair roots become smaller, and when the breast nipples become smaller, the thickness of the hair becomes thinner, and at the same time, the hair cycle becomes shorter, and the newly grown hair becomes thinner. Therefore, when the baldness progresses, the hair turns into fluffy, and the hair cycle becomes shorter, and after it grows a little, it falls out.
탈모의 원인은 유전적인 원인이 크게 자리하고 있으며, 비단 남성들만의 문제가 아니라 여성들의 탈모현상도 늘어나고 있는 상황으로 최근 심각한 문제로 대두되고 있다. 유전적 요인 외에 호르몬의 불 균형적인 분비, 사회생활의 정신적 스트레스, 대기오염 노출, 가공 식품의 섭취, 고열로 인한 공병, 영양의 불균형, 항암제 및 항 갑상선제의 복용, 경구 피임약의 투여, 샴푸, 강한 자외선이나 운동 중 흘리는 땀, 식습관, 심리적 압박감 등의 다양한 습관과 환경이 주범으로 알려졌다. The cause of hair loss is largely due to a genetic cause, and not only men's problems, but women's hair loss phenomenon is also increasing. In addition to genetic factors, unbalanced secretion of hormones, mental stress in social life, exposure to air pollution, consumption of processed foods, empty stomach caused by fever, nutritional imbalance, taking anti-cancer and anti-thyroid drugs, oral contraceptives, shampoo, strong Various habits and environments, such as ultraviolet rays or sweating during exercise, eating habits, and psychological pressure, were known as the main culprit.
현재 사용되고 있는 다양한 모발 성장 촉진을 위해 개발된 물질들은 사용시 심각한 부작용을 초래하고 그 효과 또한 미흡한 것이 실정이다.The materials developed to promote various hair growth currently being used cause serious side effects when used, and the effect is also insufficient.
선행 기술 문헌을 통해 Wnt/b-catenin 신호 전달 체계는 모낭 발달과 어른의 모발 재생에 중요한 역할을 한다고 알려졌다[Millar SE. J Invest Dermatol 2002;118:216e25;Collins CA, Kretzschmar K, Watt FM. Development 2011;138:4189e5199]. Wnt/b-catenin signaling systems have been shown in prior art literature to play an important role in hair follicle development and hair regeneration in adults [Millar SE. J Invest Dermatol 2002;118:216e25; Collins CA, Kretzschmar K, Watt FM. Development 2011;138:4189e5199].
모낭세포의 성장기 단계 동안 b-catenin을 억제시키면 모낭 메트릭스 증식을 억제하지만[Choi YS, Zhang YH, Xu MG, Yang YG, Ito M, Peng T, et al. Cell Stem Cell 2013;13:720e33], 모발 자극 복합체와 같은 Wnt/b-catenin 신호 전달 체계가 활성화되면 모낭 세포 증식을 촉진한다[Jo SJ, Choi SJ, Yoon SY, Lee JY, Park WS, Park PJ, et al. J Dermatol Sci 2013;72: 16e24;Zimber MP, Ziering C, Zeigler F, Hubka M, Mansbridge JN, Baumgartner M, et al. J Drugs Dermatol 2011;10:1308e12]. Inhibiting b-catenin during the growth phase of hair follicle cells inhibits hair follicle matrix proliferation [Choi YS, Zhang YH, Xu MG, Yang YG, Ito M, Peng T, et al. Cell Stem Cell 2013;13:720e33], promotes hair follicle cell proliferation when Wnt/b-catenin signaling system such as hair stimulating complex is activated [Jo SJ, Choi SJ, Yoon SY, Lee JY, Park WS, Park PJ , et al. J Dermatol Sci 2013;72: 16e24;Zimber MP, Ziering C, Zeigler F, Hubka M, Mansbridge JN, Baumgartner M, et al. J Drugs Dermatol 2011; 10:1308e12].
[선행 특허 문헌][Previous patent document]
대한민국 특허공개번호 제1999-021864호Republic of Korea Patent Publication No. 1999-021864
본 발명은 상기의 필요성에 의하여 안출된 것으로서 본 발명의 목적은 신규한 발모 촉진용 조성물을 제공하는 것이다.The present invention was devised by the necessity of the above, and an object of the present invention is to provide a novel composition for promoting hair growth.
상기의 목적을 달성하기 위하여 본 발명은 비타민 C에 특이적으로 결합하는 압타머를 유효성분으로 포함하는 탈모증의 예방, 치료 또는 개선용 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for the prevention, treatment or improvement of alopecia, comprising aptamer specifically binding to vitamin C as an active ingredient.
본 발명의 일 실시예에 있어서, 상기 압타머는 서열번호 1(GTGGA GGCGG TGGCC AGTCT CATAC GCGGC AG)에 기재된 염기서열로 이루어진 것이 바람직하나, 상기 서열에 하나 이상의 치환, 결손 등에 의하여 본 발명의 목적을 달성할 수 있는 모든 돌연변이체도 본 발명의 범위에 포함된다.In one embodiment of the present invention, the aptamer is preferably made of the nucleotide sequence described in SEQ ID NO: 1 (GTGGA GGCGG TGGCC AGTCT CATAC GCGGC AG), but achieves the object of the present invention by one or more substitutions, deletions, etc. in the sequence All possible mutants are also included in the scope of the present invention.
본 발명의 다른 구현에에 있어서, 상기 조성물은 발모 촉진 효과를 가지는 것이 바람직하나 이에 한정되지 아니한다.In another embodiment of the present invention, the composition is preferred to have a hair growth promoting effect, but is not limited thereto.
본 발명의 다른 구현예에 있어서, 상기 조성물은 로션, 에멀젼, 크림, 에센스 또는 스프레이 제형으로 구성된 군 중에서 선택되는 것이 바람직하나 이에 한정되지 아니한다.In another embodiment of the invention, the composition is preferably selected from the group consisting of lotions, emulsions, creams, essences or spray formulations, but is not limited thereto.
또한 본 발명은 서열번호 1에 기재된 염기서열로 이루어진 발모 촉진용 압타머를 제공한다.In addition, the present invention provides an aptamer for promoting hair growth consisting of the nucleotide sequence set forth in SEQ ID NO: 1.
이하 본 발명을 설명한다.Hereinafter, the present invention will be described.
CXXC5는 zinc-finger domain을 함유한 작은 단백질 군의 구성원이며 Wnt/b-catenin의 경로를 약화시키는 표적 유전자로, Disheeveled (Dvl) 결합 motif를 통해 Dvl 단백질과 상호 작용하여[London TB, Lee HJ, Shao YM, Zheng J. Biochem Biophys Res Commun 2004;322:326e32.], 신경 줄기 세포와 zebrafish에서 Wnt/b-catenin 신호 전달 체계의 음성 조절인자 역할을 한다[Andersson T, Sodersten E, Duckworth JK, Cascante A, Fritz N, Sacchetti P, et al. J Biol Chem 2009;284:3672e81; Kim MS, Yoon SK, Bollig F, Kitagaki J, Hur W, Whye NJ, et al. J Biol Chem 2010;285:14585e93]. CXXC5 is a member of a small group of proteins containing a zinc-finger domain and is a target gene that weakens the pathway of Wnt/b-catenin. It interacts with the Dvl protein through a Disheeveled (Dvl) binding motif [London TB, Lee HJ, Shao YM, Zheng J. Biochem Biophys Res Commun 2004;322:326e32.], acts as a negative regulator of the Wnt/b-catenin signaling system in neural stem cells and zebrafish [Andersson T, Sodersten E, Duckworth JK, Cascante A, Fritz N, Sacchetti P, et al. J Biol Chem 2009;284:3672e81; Kim MS, Yoon SK, Bollig F, Kitagaki J, Hur W, Whye NJ, et al. J Biol Chem 2010;285:14585e93].
따라서 Wnt/b-catenin 신호 전달 체계의 Dvl1_PDZ domain과 CXXC5단백질의 결합 여부가 탈모 방지에 중요한 역할을 하는 것을 확인하였으며[Lee SH, Seo SH, et al. Journal of Investigative Dermatology (2017) 137, 2260e2269; doi:10.1016/j.jid.2017.04.038.], 부작용 없이 탈모를 방지하고 발모를 촉진할 수 있는 물질을 개발하고자 노력한 결과, Aptamin C가 모발성장을 촉진하는 효과가 있음을 확인하고 본 발명을 완성하였다. Therefore, it was confirmed that the binding of the Dvl1_PDZ domain and CXXC5 protein of the Wnt/b-catenin signaling system plays an important role in preventing hair loss [Lee SH, Seo SH, et al. Journal of Investigative Dermatology (2017) 137, 2260e2269; doi:10.1016/j.jid.2017.04.038.], As a result of trying to develop a substance that can prevent hair loss and promote hair growth without side effects, it was confirmed that Aptamin C has an effect of promoting hair growth and the present invention Completed.
본 발명에서 압타민 C는 비타민 C에 특이적으로 결합하는 압타머를 의미하는 것으로, 본 발명에서는 서열번호 1의 압타머를 의미하나 상기 서열에 하나 이상의 치환, 결손 등에 의하여 본 발명의 목적을 달성할 수 있는 모든 돌연변이체도 본 발명의 범위에 포함된다. In the present invention, aptamine C refers to an aptamer that specifically binds to vitamin C. In the present invention, it means the aptamer of SEQ ID NO: 1, but achieves the object of the present invention by one or more substitutions, deletions, etc., in the sequence. All possible mutants are also included in the scope of the present invention.
본 발명에서 탈모 예방, 치료 또는 개선이란 용어는 발모 촉진이라는 용어와 혼용이 가능하다.In the present invention, the term hair loss prevention, treatment, or improvement can be used interchangeably with the term hair growth promotion.
본 발명은 압타머를 유효성분으로 포함하는 탈모방지 또는 발모 촉진용 조성물을 제공하는 것이 특징이다. The present invention is characterized by providing a composition for preventing hair loss or promoting hair growth comprising aptamer as an active ingredient.
이때, 상기 발모 촉진용 조성물 중의 압타머의 함량은 0.00001 중량% 내지 2 중량%인 것이 바람직하고, 0.0001 중량% 내지 1 중량%인 것이 더욱 바람직하다.At this time, the content of the aptamer in the composition for promoting hair growth is preferably 0.00001% by weight to 2% by weight, and more preferably 0.0001% by weight to 1% by weight.
한편, 본 발명에 따른 탈모 방지 및 발모 촉진용 조성물은 유효성분으로서 압타머 이외에도, 주 효과를 완화하지 않는 범위 내에서 약제학적으로 허용가능한 담체를 더 포함할 수도 있으며, 더 나아가 피부 흡수를 촉진하는 물질 및 효능을 향상시키는 기타 물질을 더 포함할 수도 있다. On the other hand, the composition for preventing hair loss and promoting hair growth according to the present invention, in addition to aptamer as an active ingredient, may further include a pharmaceutically acceptable carrier within a range that does not alleviate the main effect, and further promotes skin absorption. It may further include substances and other substances that enhance efficacy.
상기 담체로는 부형제, 결합제, 활택제, 붕괴제, 윤활제, 피복제, 유화제, 현탁제, 용제, 안정화제, 흡수조제, 주사용수 및 등장화제로 이루어진 군으로부터 선택된 하나 이상의 담체를 예로 들 수 있다. 구체적으로, 결합제로는 락토오스, 사카로오스, 솔비톨, 만니톨, 전분, 아밀로펙틴, 셀룰로오스 또는 젤라틴 등을, 부형제로는 디칼슘 포스페이트 등을, 붕괴제로는 옥수수 전분 또는 고구마 전분 등을, 윤활제로는 스테아린산 마그네슘, 스테아린산 칼슘, 스테아릴푸마르산 나트륨 또는 폴리에틸렌글리콜 왁스 등을 예로 들 수 있다.Examples of the carrier include one or more carriers selected from the group consisting of excipients, binders, lubricants, disintegrants, lubricants, coating agents, emulsifiers, suspending agents, solvents, stabilizers, absorption aids, water for injection, and isotonic agents. . Specifically, as the binder, lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose or gelatin, etc., excipients such as dicalcium phosphate, corn starch or sweet potato starch as a disintegrant, magnesium stearate as a lubricant, Examples include calcium stearate, sodium stearyl fumarate, or polyethylene glycol wax.
또한 상기 압타민 C를 함유하는 발모 촉진용 조성물은 시중에서 통상 발모제로 사용되고 있는 로션, 에멀젼, 크림, 에센스 또는 스프레이 제형으로 구성된 군 중에서 선택될 수 있으나, 특정 제형에 한정되는 것은 아니다.In addition, the composition for promoting hair growth containing aptamine C may be selected from the group consisting of lotions, emulsions, creams, essences, or spray formulations commonly used as hair growth agents, but is not limited to a specific formulation.
본 발명을 통하여 알 수 있는 바와 같이, 본 발명의 압타민C는 Dvl1_PDZ domain과 Aptamin C가 특이적으로 결합하고, 동물 실험 결과 발모 촉진 효과를 나타내서 탈모 예방, 치료 또는 개선용 화장품, 건강식품 또는 의약 분야에 적용이 가능하다. As can be seen through the present invention, the aptamine C of the present invention specifically binds the Dvl1_PDZ domain and Aptamin C, and exhibits a hair growth promoting effect as a result of animal experiments, thus preventing, treating or improving hair loss, cosmetics, health food or medicine It can be applied to fields.
도 1은 Dvl1_PDZ domain과 Aptamin C의 결합 여부를 확인하기 위해 크로마토그래피를 이용하여 Dvl1_PDZ domain 단백질의 크기 변화를 측정한 결과를 나타낸 그림.
도 2는 형광 측정법을 사용하여 Dvl1_PDZ domain 단백질과 Aptamin C의 결합력을 측정한 결과를 나타낸 그림,
도 3은 Aptamin C의 모발 성장촉진 효과를 확인하기 위한 동물 실험 결과를 나타낸 사진. Figure 1 is a diagram showing the results of measuring the size change of the Dvl1_PDZ domain protein using chromatography to confirm the binding of the Dvl1_PDZ domain and Aptamin C.
Figure 2 is a diagram showing the results of measuring the binding force of the Dvl1_PDZ domain protein and Aptamin C using fluorescence measurement method,
Figure 3 is a photograph showing the results of animal experiments to confirm the effect of promoting hair growth of Aptamin C.
이하 비한정적인 실시예를 통하여 본 발명을 더욱 상세하게 설명한다. 단 하기 실시예는 본 발명을 예시하기 위한 의도로 기재한 것으로서 본 발명의 범위는 하기 실시예에 의하여 제한되는 것으로 해석되지 아니한다.Hereinafter, the present invention will be described in more detail through non-limiting examples. However, the following examples are intended to illustrate the present invention and the scope of the present invention is not to be construed as being limited by the following examples.
실시예Example 1: One: SELEXSELEX
Dvl1_PDZ domain에 대한 SELEX를 ~ 1020 독특한 올리고뉴크레오타이드로 구성된 DNA 라이브러리[IDT (Intergrated DNA Technologies)사에서 구입]를 사용하여 수행하였다. SELEX for the Dvl1_PDZ domain was performed using a DNA library consisting of ˜10 20 unique oligonucleotides (purchased from IDT (Intergrated DNA Technologies)).
사용된 버퍼 조성은 다음과 같다: 50 mM Sodium Acetate pH 5.5 (Sigma), 1 mM MgCl2 (Sigma), 0.05% Tween 20 (Sigma), 1% BSA (Sigma) 및 0.1 mM Dvl1_PDZ domain 단백질. SELEX를 타겟에 대한 압타머의 결합시간을 감소시키고, 버퍼 조성을 변경하고 자유 분자 용출에서 타겟의 농도를 감소시켜 변경하였다.The buffer composition used was: 50 mM Sodium Acetate pH 5.5 (Sigma), 1 mM MgCl2 (Sigma), 0.05% Tween 20 (Sigma), 1% BSA (Sigma) and 0.1 mM Dvl1_PDZ domain protein. SELEX was changed by reducing the binding time of the aptamer to the target, changing the buffer composition and decreasing the concentration of the target in free molecular elution.
실시예Example 2: 크로마토그래피를 이용한 2: Chromatography Dvl1Dvl1 __ PDZPDZ domain 단백질의 크기 변화를 측정 Measure the size change of domain protein
Dvl1_PDZ domain과 Aptamin C의 결합 여부를 확인하기 위해 크로마토그래피를 이용하여 Dvl1_PDZ domain 단백질의 크기 변화를 측정하였다.To confirm the binding of the Dvl1_PDZ domain and Aptamin C, the size change of the Dvl1_PDZ domain protein was measured using chromatography.
도 1에서 알 수 있는 바와 같이, Dvl1_PDZ domain 단백질을 정제하여 1 mM의 단백질을 크로마토그래피를 진행하였을 때 약 9 kDa의 크기를 가지는 것을 확인하였으며, Dvl1_PDZ domain 단백질에 Aptamin C 0.1 mM을 첨가하여 크로마토그래피를 진행하였을 때 약 20 kDa의 피크와 9 kDa의 피크를 확인할 수 있었다. As can be seen in Figure 1, when the Dvl1_PDZ domain protein was purified and chromatographed 1 mM protein, it was confirmed to have a size of about 9 kDa, and chromatographed by adding Aptamin C 0.1 mM to the Dvl1_PDZ domain protein When proceeding, it was confirmed that the peak of about 20 kDa and the peak of 9 kDa.
이는 Aptamin C (약 10 kDa)와 Dvl1_PDZ domain 단백질(9 kDa)이 1:1 결합을 한다는 것을 확인할 수 있었다. This confirmed that Aptamin C (about 10 kDa) and Dvl1_PDZ domain protein (9 kDa) had 1:1 binding.
Aptamin C가 Dvl1 단백질의 PDZ domain에만 특이적으로 결합하는지 확인하기 위하여 Dvl1_DAX domain 단백질에 Aptamin C를 첨가하여 크로마토그래피를 진행하였을 때 Dvl1_PDZ domain 단백질과 다른 양상으로 약 10 kDa의 피크만을 확인할 수 있었다. Dvl1_DAX domain 단백질과 Aptamin C의 크기는 모두 약 9~10 kDa로 유사하며 결합을 하지 않을 시 같은 피크에서 발견된다. 이를 바탕으로 Aptamin C는 Dvl1_PDZ domain 단백질과 특이적으로 결합하는 것을 확인하였다. In order to confirm that Aptamin C specifically binds only to the PDZ domain of the Dvl1 protein, when a chromatography was performed by adding Aptamin C to the Dvl1_DAX domain protein, only a peak of about 10 kDa was identified in a different pattern from the Dvl1_PDZ domain protein. The size of the Dvl1_DAX domain protein and Aptamin C are both about 9-10 kDa, and are found at the same peak when not bound. Based on this, it was confirmed that Aptamin C specifically binds to the Dvl1_PDZ domain protein.
동일한 방법으로 Aptamin C가 Wnt/b-catenin 신호전달 체계에 관여하는 다른 단백질들과 결합 유무를 확인하였으며 Wnt/b-catenin 신호전달 체계의 중요 단백질로 알려진 Axin 단백질과 결합실험 결과 결합을 하지 않는 것으로 확인되었다. 따라서 Aptamin C는 Dvl1_PDZ domain 단백질에 특이적으로 결합한다는 것을 확인하였다. In the same way, Aptamin C confirmed the presence or absence of binding to other proteins involved in the Wnt/b-catenin signaling system, and did not bind to Axin protein, which is known as an important protein of the Wnt/b-catenin signaling system. Was confirmed. Therefore, it was confirmed that Aptamin C specifically binds to the Dvl1_PDZ domain protein.
추가적으로 무작위의 시퀀스를 가지는 30mer의 DNA 라이브러리를 이용하여 Dvl1_PDZ domain 단백질과 결합 여부를 확인하였다. 확인결과 무작위 Aptamer(N30, Random sequence)와 Dvl1_PDZ domain 단백질을 섞은 후 크로마토그래피를 하였을시 결합하지 않는 것을 확인하였다. 따라서 Dvl1_PDZ domain에 특이적으로 Aptamin C만이 결합하는 것을 확인할 수 있었다.Additionally, it was confirmed whether or not to bind to the Dvl1_PDZ domain protein using a 30mer DNA library with a random sequence. As a result of the analysis, it was confirmed that a random Aptamer (N30, Random sequence) and Dvl1_PDZ domain protein were mixed and then not bound when chromatographed. Therefore, it was confirmed that only Aptamin C binds specifically to the Dvl1_PDZ domain.
실시예Example 3: 형광 측정법을 사용하여 3: Using fluorescence measurement Dvl1Dvl1 __ PDZPDZ domain 단백질과 domain protein AptaminAptamin C의 결합력 측정 Measure the bonding force of C
형광 측정법을 사용하여 Dvl1_PDZ domain 단백질과 Aptamin C의 결합력을 측정하였다. The binding force between the Dvl1_PDZ domain protein and Aptamin C was measured using a fluorescence measurement method.
도 2에서 알 수 있는 바와 같이, Dvl1_PDZ domain 단백질 100uM 대조군으로 시작하여 Aptamin C를 10 uM부터 100 uM 까지 10 uM씩 농도를 높여가며 실험을 진행하였으며, 결합력이 약 280nM 로 강한 결합을 하는 것을 확인하였다.As can be seen in Figure 2, starting with the Dvl1_PDZ domain protein 100uM control, the experiment was performed by increasing the concentration of Aptamin C by 10 uM from 10 uM to 100 uM, and the binding strength was confirmed to be strong with about 280 nM. .
실시예Example 4: 동물 실험 4: Animal experiment
Aptamin C의 모발 성장촉진 효과를 확인하기 위해 휴지기에 들어간 6주령 된 C57BL/6 마우스의 등 부위의 모발을 제거하고 모발이 제거된 부위에 대조군에는 수액을 처리하였으며 처리군에는 비타민C 1mg/ml, Aptamin C 0.02mg/ml, 미녹시딜 10mg/ml로 매일 09시, 18시 2회씩 스프레이를 이용해 도포하였다. In order to confirm the effect of promoting hair growth of Aptamin C, the hair of the back of the 6-week-old C57BL/6 mouse that entered the resting period was removed, and the sap was treated in the control group at the site where the hair was removed, and vitamin C 1mg/ml in the treatment group, Aptamin C 0.02mg/ml, minoxidil 10mg/ml was applied with a spray twice a day at 09:00 and 18:00.
도 3에서 알 수 있는 것과 같이, 동물 실험 결과 대조군에 비해 Aptamin C와 미녹시딜이 처리된 군에서 모발의 성장이 촉진되었음을 알 수 있었으며, 특히 Atpamin C가 처리된 군에서 모발 성장이 크게 증가한 것을 확인할 수 있었다.As can be seen in Figure 3, as a result of animal experiments, it was found that the growth of hair was promoted in the group treated with Aptamin C and minoxidil compared to the control group, and in particular, it was confirmed that the hair growth was significantly increased in the group treated with Atpamin C. there was.
<110> Nexmos Co., Ltd. <120> A COMPOSITION FOR PREVENTING, TREATING OR IMPROVING ALOPECIA COMPRISING APTAMIN C <130> P18-0132HS <160> 1 <170> KopatentIn 2.0 <210> 1 <211> 32 <212> DNA <213> Artificial Sequence <220> <223> Aptamer <400> 1 gtggaggcgg tggccagtct catacgcggc ag 32 <110> Nexmos Co., Ltd. <120> A COMPOSITION FOR PREVENTING, TREATING OR IMPROVING ALOPECIA COMPRISING APTAMIN C <130> P18-0132HS <160> 1 <170> KopatentIn 2.0 <210> 1 <211> 32 <212> DNA <213> Artificial Sequence <220> <223> Aptamer <400> 1 gtggaggcgg tggccagtct catacgcggc ag 32
Claims (5)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180157134A KR102166356B1 (en) | 2018-12-07 | 2018-12-07 | A composition for preventing, treating or improving alopecia comprising aptamin c |
| PCT/KR2019/016420 WO2020116849A2 (en) | 2018-12-07 | 2019-11-27 | Composition for preventing, treating or alleviating alopecia, comprising aptamin c as active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180157134A KR102166356B1 (en) | 2018-12-07 | 2018-12-07 | A composition for preventing, treating or improving alopecia comprising aptamin c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200069737A true KR20200069737A (en) | 2020-06-17 |
| KR102166356B1 KR102166356B1 (en) | 2020-10-15 |
Family
ID=70973904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180157134A KR102166356B1 (en) | 2018-12-07 | 2018-12-07 | A composition for preventing, treating or improving alopecia comprising aptamin c |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR102166356B1 (en) |
| WO (1) | WO2020116849A2 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060110017A (en) * | 2005-01-13 | 2006-10-24 | (주)트리코진 | Composition for stimulating growth of dermal papilla cells and promoting hair follicle growth comprising vitamin c derivatives |
| US20070112064A1 (en) * | 2003-07-24 | 2007-05-17 | Lyles Mark B | Nucleic acid antioxidant compositions, methods for obtaining such compositions and formulations thereof |
| KR20180054508A (en) * | 2016-03-04 | 2018-05-24 | 주식회사 넥스모스 | Antioxidant anti-oxidation method, materials and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100348155B1 (en) * | 2000-04-28 | 2002-08-09 | 김상묵 | The hair-growing agent composition which is contained the extract from natural phellinus linteus and preparation method using the same |
| KR100796904B1 (en) * | 2006-05-04 | 2008-01-22 | 신석봉 | Compositions for promoting hair growth containing complexes of stabilized Vitamin C or Vitamin C derivatives |
-
2018
- 2018-12-07 KR KR1020180157134A patent/KR102166356B1/en active IP Right Grant
-
2019
- 2019-11-27 WO PCT/KR2019/016420 patent/WO2020116849A2/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070112064A1 (en) * | 2003-07-24 | 2007-05-17 | Lyles Mark B | Nucleic acid antioxidant compositions, methods for obtaining such compositions and formulations thereof |
| KR20060110017A (en) * | 2005-01-13 | 2006-10-24 | (주)트리코진 | Composition for stimulating growth of dermal papilla cells and promoting hair follicle growth comprising vitamin c derivatives |
| KR20180054508A (en) * | 2016-03-04 | 2018-05-24 | 주식회사 넥스모스 | Antioxidant anti-oxidation method, materials and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020116849A9 (en) | 2020-09-24 |
| WO2020116849A2 (en) | 2020-06-11 |
| WO2020116849A3 (en) | 2020-07-23 |
| KR102166356B1 (en) | 2020-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pang et al. | Quercetin stimulates bone marrow mesenchymal stem cell differentiation through an estrogen receptor-mediated pathway | |
| Li et al. | Linarin promotes osteogenic differentiation by activating the BMP-2/RUNX2 pathway via protein kinase A signaling | |
| Singh et al. | Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol | |
| Miron et al. | The effect of enamel matrix proteins on the spreading, proliferation and differentiation of osteoblasts cultured on titanium surfaces | |
| Benitah et al. | ROCK and nuclear factor-κB–dependent activation of cyclooxygenase-2 by Rho GTPases: effects on tumor growth and therapeutic consequences | |
| Cheng et al. | Sinusoidal electromagnetic field stimulates rat osteoblast differentiation and maturation via activation of NO–cGMP–PKG pathway | |
| Tanaka et al. | In vivo and in vitro effects of insulin-like growth factor-I (IGF-I) on femoral mRNA expression in old rats | |
| Yang et al. | Kaempferol stimulates bone sialoprotein gene transcription and new bone formation | |
| Asparuhova et al. | Bone-conditioned medium contributes to initiation and progression of osteogenesis by exhibiting synergistic TGF-β1/BMP-2 activity | |
| CN102459587A (en) | Hepcidin binding nucleic acids | |
| Yokota et al. | Effects of salubrinal on development of osteoclasts and osteoblasts from bone marrow-derived cells | |
| CN103347531B (en) | skin collagen production promoter | |
| Chiu et al. | The JAK inhibitor Tofacitinib inhibits structural damage in osteoarthritis by modulating JAK1/TNF-alpha/IL-6 signaling through Mir-149-5p | |
| Song et al. | T-614 promotes osteoblastic cell differentiation by increasing Dlx5 expression and regulating the activation of p38 and NF-κB | |
| US6174541B1 (en) | Skin aging and wound treatment using cell migration agents | |
| Kawano et al. | Royal jelly regulates the proliferation of human dermal microvascular endothelial cells through the down-regulation of a photoaging-related microRNA | |
| Jiang et al. | Upregulation of cell proliferation via Shc and ERK1/2 MAPK signaling in SaOS-2 osteoblasts grown on magnesium alloy surface coating with tricalcium phosphate | |
| JP6621544B2 (en) | Pharmaceutical composition for preventing and treating cancer or cancer metastasis comprising FSTL1 protein as an active ingredient | |
| KR102166356B1 (en) | A composition for preventing, treating or improving alopecia comprising aptamin c | |
| Kawai et al. | Prevention of skeletal muscle atrophy in vitro using anti-ubiquitination oligopeptide carried by atelocollagen | |
| Liu et al. | Panax notoginseng saponin promotes bone regeneration in distraction osteogenesis via the tgf-β1 signaling pathway | |
| WO2019140300A1 (en) | Compositions and methods to promote thymic regeneration | |
| WO2022145439A1 (en) | Muscular atrophy inhibitor and method for inhibiting muscular atrophy | |
| KR20190014454A (en) | Composition for Inhibition or Treatment of Keloids and Hypertrophic Scar Comprising CRIF1 Antagonist | |
| Onodera et al. | Growth factor-induced expression of macrophage migration inhibitory factor in osteoblasts: relevance to the plasminogen activator system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |